Treatment and prophylaxis of influenza.
Reference:
Aoki FY, Allen UD, Stiver HG, et al. The use of antiviral drugs for influenza: A foundation document for practitioners. AMMI Canada Guideline. Canadian Journal of Infectious Disease and Medical Microbiology; (24); Suppl C. 2013.
GI upset common
Rare - Stevens Johnson
Neuropsychiatric side effects reported
No significant interactions
LU code for outpatient use
LU 371 For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B (Note: Network will limit supply to 6 weeks) LU Authorization Period: 1 year
LU 372 For the treatment (max: 75mg BID) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis. (Note: Network will limit supply to 5 days) LU Authorization period: 1 year
*The outbreak must be confirmed by Public Health
LU 639 For treatment of individuals during the 2022-2023 Influenza season who are at high risk* of complications from influenza infection and have either:
*High risk of complications from influenza infection is defined by the presence of one or more of the following;
Maximum dosage: 75mg BID for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
LU Authorization Period: 6 months
Antimicrobial class: Antiviral - Neuraminidase inhibitor
Pregnancy category: C
Average serum half life: 2 hours
Lung penetration: Therapeutic